Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

Trial Profile

Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs GSK 3390107A (Primary) ; RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms PREVAIL
  • Most Recent Events

    • 17 Nov 2016 Planned number of patients changed from 28170 to 1500.
    • 18 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2020.
    • 10 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top